Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Os-Cal, Citracal Parity Claims Modification Recommended By NAD

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's ad claims that its Os-Cal calcium supplement is absorbed "just as well as" Mission Pharmacal's Citracal may be misleading without "more clearly communicat[ing] the basis of the declared comparison," the National Advertising Division of the Council of Better Business Bureaus concludes in a recently released Case Report
Advertisement

Related Content

Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
Mission Pharmacal Citracal superior calcium bioavailability claims unsupported -- NAD.
Mission Pharmacal Citracal superior calcium bioavailability claims unsupported -- NAD.

Topics

Advertisement
UsernamePublicRestriction

Register

PS093528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel